![](https://library.celltelligence.com/wp-content/uploads/2021/05/Autolus_Ziopharm_Cellectis_Earnings.png)
$0
Will Next-Generation Modules be Enough to Differentiate Autolus’s Products? Ziopharm Deprioritizes Several Programs; What Targets and Indications Could Cellectis Pursue Next? Autolus, Ziopharm, and Cellectis Q1 2021 Earnings Call Summaries
On Thursday, May 6, Autolus held their Q1 2021 earnings call (press release / presentation) highlighting several anticipated AUTO1 data updates in 2021 while providing details on their next-generation programs and manufacturing strategy. On the same day, Ziopharm presented their Q1 2021 results (press release / presentation) announcing the deprioritization of their controllable IL-12 gene therapy and their allogeneic CD19 RPM programs. Furthermore, Cellectis reported their Q1 2021 financial results (press release) commenting on the progress of their clinical program and a series of R&D events to be held between May 24 — 28.